NHS patients denied new lung cancer drug after another NICE ...

Certain untreated lung cancer patients on England's NHS will have to make do with older drugs after NICE ruled in final guidance that AstraZeneca’s Tagrisso (osimertinib) is not cost-effect

The three biggest challenges in lung cancer, and how researc...

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research.

AZ and MSD's Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient

MiNA’s gene-activating tech wins an AstraZeneca alliance

AstraZeneca kicks off 2020 with double win in US and China

AstraZeneca has started 2020 strongly, with the FDA granting a fast review for its big-selling Farxiga in heart failure and a key drug approval in China.

AZ, Merck add pancreatic cancer to Lynparza’s growing use li...